ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2026
Prosthesis-Patient Mismatch in All-Comer Patients Undergoing Newer-Generation Self-Expanding Transcatheter Aortic Valve Replacement.
Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProsthesis-patient mismatch (PPM) after transcatheter aortic valve replacement (TAVR) may affect outcomes, but its incidence and impact with contemporary self-expanding valves remain unclear.
aimsEvaluate the frequency, predictors, and long-term outcomes of PPM in a real-world TAVR population.
methodsWe analyzed patients ≥ 18 years undergoing TAVR with current-generation self-expanding valves (Evolut FX/FX+, PRO/PRO+, Navitor, Navitor Vision) from a prospectively maintained institutional database (2017-2025). Predicted PPM was defined according to VARC-3 criteria, with all-cause mortality and heart failure hospitalization as the primary outcomes.
resultsAmong 2989 patients (median age 80 [75-85], 50.8% female) receiving Evolut (83.3%) or Navitor (16.7%) valves, PPM occurred in 5.0% (moderate 3.7%, severe 1.3%) and declined from 6.5% in 2017 to 2.7% in 2025 (p = 0.002). Independent predictors of PPM included female sex (OR 2.04, 95% CI 1.06-3.99, p = 0.035) and valve-in-valve procedures (OR 9.60, 95% CI 3.82-25.64, p < 0.001), whereas use of the Navitor valve was associated with markedly lower odds (OR 0.07, 95% CI 0.00-0.32, p = 0.009). Patients with PPM demonstrated significantly higher post-procedural transvalvular gradients and reduced aortic valve areas (both p < 0.001). PPM was not associated with adverse long-term clinical outcomes, with no significant differences in 5-year all-cause mortality (HR 0.84, 95% CI 0.45-1.57, p = 0.592) or heart failure hospitalization (HR 1.22, 95% CI 0.84-1.77, p = 0.295).
conclusionIn this contemporary TAVR cohort, PPM was infrequent, and its incidence declined over time. Female sex and valve-in-valve procedures independently predicted PPM. Despite adverse hemodynamic profiles, PPM was not associated with early or long-term adverse clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.